Welcome to our dedicated page for Serina Therapeutics SEC filings (Ticker: SER), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Serina Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Serina Therapeutics's regulatory disclosures and financial reporting.
Serina Therapeutics, Inc. reported that Chief Executive Officer Steven A. Ledger acquired 10,100 shares of common stock as a grant/award on May 26, 2026. The award is recorded at $1.93 per share, and his directly held common stock after this transaction totals 10,100 shares.
Serina Therapeutics, Inc. reported that SVP, CMC & Formulation Tenjarla Srini received a grant of stock options covering 85,558 shares of common stock. The options have an exercise price of $1.89 per share and expire on May 21, 2036.
According to the vesting terms, 12/48ths of the options vest 12 months after the vesting commencement date, and 1/48th vests monthly thereafter until fully vested. Following this grant, Srini holds 85,558 derivative securities directly, reflecting a routine compensation-related award rather than an open-market trade.
Serina Therapeutics Chief Executive Officer Steven A. Ledger received a grant of stock options for 380,825 shares of Common Stock at an exercise price of $1.89 per share. These options expire on May 21, 2036 and vest over four years, with 12/48ths vesting after 12 months and the remainder vesting in equal monthly installments.
Serina Therapeutics, Inc. reported that Chief Financial Officer Gregory S. Curhan received a compensation grant of stock options covering 123,019 shares of common stock at an exercise price of $1.89 per share. The options vest over four years, with 12/48ths vesting one year after the Vesting Commencement Date and 1/48th each month thereafter, and expire on May 21, 2036. Following this award, Curhan holds stock options for 123,019 underlying shares directly.
Serina Therapeutics, Inc. Chief Scientific Officer Moreadith Randall received a grant of stock options covering 85,558 shares of common stock. The options have an exercise price of $1.89 per share and expire on May 21, 2036.
These options were granted at no upfront cost and are held directly. According to the vesting terms, 12/48ths of the options vest twelve months after the vesting commencement date, with an additional 1/48th vesting each month thereafter until fully vested.
Serina Therapeutics director Karen J. Wilson reported open-market purchases of Serina Therapeutics, Inc. common stock. She bought 10,000 shares at a price of $1.77 per share on May 21, 2026 and 10,000 shares at $1.93 per share on May 22, 2026.
After these transactions, Wilson directly owns 20,000 common shares. Footnotes state each reported price is a weighted average for multiple trades, with actual purchase prices ranging from $1.76 to $1.79 and from $1.90 to $1.95 per share.
Serina Therapeutics director Marshall Richard Peter bought 12,183 shares of common stock in an open-market transaction. The purchase occurred on May 19, 2026 at a weighted average price of $1.65 per share, with trade prices ranging from $1.59 to $1.73. Following this transaction, he directly holds 12,183 shares of Serina Therapeutics common stock.
Serina Therapeutics, Inc. files a registration statement to permit the resale of up to 16,450,442 shares of Common Stock by specified selling stockholders pursuant to a Registration Rights Agreement.
The shares consist of 954,759 PIPE Shares, 8,467,501 Pre-Funded Warrant Shares, 4,711,129 Redeemable Warrant Shares, and 2,317,053 Series A Conversion Shares. The Company will not receive proceeds from these resales, although it may receive proceeds from any cash exercise of the Pre-Funded Warrants or Redeemable Warrants, which it intends to use for working capital and general corporate purposes. Shares outstanding were 14,997,505 as of May 10, 2026.
Serina Therapeutics reported a wider first-quarter 2026 net loss but significantly strengthened its balance sheet and advanced its lead Parkinson’s program. Net loss attributable to common stockholders was $6.9 million, or $0.58 per share, compared with $4.8 million, or $0.49 per share, a year earlier, driven partly by a $1.6 million non-cash loss tied to amending a convertible note.
The company closed a $21.2 million private placement of common stock and warrants in March and April 2026, helping lift cash and cash equivalents to $24.5 million as of March 31, 2026, up from $3.1 million at year-end 2025. Stockholders’ equity shifted from a small deficit to $17.6 million. The financing also triggered automatic conversion of all Series A preferred stock into common shares.
Serina’s Phase 1b registrational clinical study of SER-252 in advanced Parkinson’s disease is underway, with the first patient dosed in February 2026. The company expects to complete enrollment and dosing of Cohort 1 by the end of the third quarter of 2026 and is targeting TFL data from the single-ascending-dose study arm in the first half of 2027.